Head-To-Head Survey: Creative Medical Technology (NASDAQ:CELZ) & Arcellx (NASDAQ:ACLX)

Creative Medical Technology (NASDAQ:CELZ) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Volatility & Risk

Creative Medical Technology has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.

Insider and Institutional Ownership

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 96.0% of Arcellx shares are owned by institutional investors. 2.8% of Creative Medical Technology shares are owned by insiders. Comparatively, 8.4% of Arcellx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Creative Medical Technology and Arcellx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	0	0	0	0	0.00
Arcellx	0	0	13	1	3.07

Arcellx has a consensus target price of $111.33, indicating a potential upside of 63.49%. Given Arcellx’s stronger consensus rating and higher probable upside, analysts plainly believe Arcellx is more favorable than Creative Medical Technology.

Profitability

This table compares Creative Medical Technology and Arcellx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-63.05%	-60.42%
Arcellx	-25.94%	-8.28%	-5.21%

Valuation and Earnings

This table compares Creative Medical Technology and Arcellx”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$14,000.00	441.47	-$5.29 million	($3.81)	-0.63
Arcellx	$76.81 million	48.86	-$70.69 million	($2.99)	-22.78

Creative Medical Technology has higher earnings, but lower revenue than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Summary

Arcellx beats Creative Medical Technology on 10 of the 15 factors compared between the two stocks.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

About Arcellx

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company’s preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.